Back to screener
Transgene Biotek Ltd.
₹2.73
▲ 0.04 (+1.49%) today
Latest quote · Yahoo Finance
Market Cap
₹21 Cr
P/E (TTM)
—
P/B
2.5
Book Value
₹1.11
ROE
-19.2%
Div Yield
—
D/E
2.05
EPS (TTM)
₹-0.21
52W High
₹4.39
52W Low
₹1.83
Sales Growth
+21.20%
Profit Growth
—
Day High
₹2.91
Day Low
₹2.67
Volume
6,468
Fundamentals refreshed 18 hr ago · Statements just now · Source: Yahoo Finance
Quick Take
- • Trading at n/a trailing earnings
- • Moderate ROE at -19.2%
- • Leveraged balance sheet (D/E 2.05)
- • No dividend data
- • Operating margin -165.8% · Net margin 0.0%
- • Profit growth — YoY · Beta 0.97
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 0 | — | — |
| Operating Profit | -0 | — | — |
| Net Profit | -0 | — | — |
| EPS (₹) | -0.05 | +16.67% | +16.67% |
OPM -97.0% · Net margin -648.3% · prev quarter OPM -239.3%
Shareholding Pattern
Numbers in percentages · Source: Yahoo Finance
Promoters / Insiders21.70%
Public & Others78.30%
About the company
From latest AR & concall Reading the latest annual report and earnings call… (1–3 min on first visit)
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
